Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia
Febrile Neutropenia
About this trial
This is an interventional treatment trial for Febrile Neutropenia focused on measuring Febrile neutropenia, Unexplained fever, Duration, Short-term antibiotic treatment
Eligibility Criteria
Inclusion Criteria:
- Adults >18 years providing signed informed consent
- Patients with solid tumors, lymphoma, multiple myeloma or chronic lymphocytic leukemia, regardless of disease status or previous chemotherapy
- Documented febrile neutropenia
- No clinically or microbiologically documented infection after 72 hours
Exclusion Criteria:
- Previous enrollment in this study
- Concurrent participation in another interventional trial
- Severe sepsis or septic shock
- Acute leukemia, autologous or allogeneic hematopoietic stem-cell transplantation
- Diarrhea suspected by treating physician to be Irinotecan induced
- Any antibiotic treatment for >48h in the last week before enrollment
Sites / Locations
- Rabin Medical Center, Beilinson Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Early antibiotic discontinuation
Usual practice
Antibiotic treatment stopped after 72h, regardless of fever.The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
Antibiotic treatment continued according to accepted guidelines and current clinical practice. The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.